VEGFA and small cell lung carcinoma: In mice subcutaneously injected with VEGF-secreting human small-cell lung cancer cells (SBC-3/VEGF), NK012 markedly enhanced SN-38 distribution and accumulation in tumors due to the EPR effect, promoted by the hypervascularity and hyperpermeability induced by VEGF, resulting in remarkably higher antitumor activity when compared with CPT-11 [141].